Cohort A: vilobelimab
BP-ARDS-P2-001 (Master Record)
Phase 2 small_molecule active
Quick answer
Cohort A: vilobelimab for Acute Respiratory Distress Syndrome (ARDS) is a Phase 2 program (small_molecule) at Edesa Biotech with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Edesa Biotech
- Indication
- Acute Respiratory Distress Syndrome (ARDS)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active